PTC Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PTC Therapeutics, Inc.
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Novartis is trying its luck with capmatinib on the accelerated assessment front at the European Medicines Agency. Gilead and Astellas/Seagen have secured fast-track review for their respective potential new products while Sesen Bio and Amryt Pharma are dealing with rejection.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
One out of seven requests for the accelerated assessment of planned EU marketing authorization applications is known to have been granted this year to date.
- Antisense, Oligonucleotides
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Agilis Biotherapeutics, Inc.
- Censa Pharmaceuticals Inc.